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Many patients with cancer have benefited from the introduction of
new drug and treatment regimens. This is reflected both in an
increase in survival and improved quality of life of patients under-
going different cancer treatments (Hamilton, 1992). As practise
becomes more evidence-based, the medical profession and
governmental agencies recognize that the most accurate way of
evaluating new treatments is within a randomized clinical trial
(RCT) (Smyth et al, 1994). Unfortunately, despite the fact that
many UK clinicians are committed to the concept of a trial, fewer
than 5% of UK patients are recruited, although the figure varies
according to the cancer site and treatment centre (Stenning, 1992;
Leonard, 1997).
Studies examining the reason for low recruitment note that non-
participation is influenced by factors affecting both the physician
and the patient, as well as the eligibility criteria in strict trial proto-
cols (Taylor and Kelner, 1987; Cook-Gotay, 1991; Fallowfield et
al, 1997). The UK Co-ordinating Committee on Cancer Research
working party identified several factors affecting clinician partici-
pation, particularly for those doctors practising in non-teaching
hospitals. Among these were time constraints and lack of support
staff to help discuss and coordinate the pragmatic aspects of
randomized trials (Slevin et al, 1995; Smyth et al, 1994).
Many patients presume that the cancer specialist will know
exactly how to treat the illness. They will invest trust in the
specialist, even before meeting them, and would not anticipate
a consultation in which uncertainty and randomization are
discussed. The notion of random assignment may be contrary to
how a patient may view the delivery of cancer treatment (Toynbee,
1997). In addition, the patient may interpret the word ‘trial’ to
mean that they are to take part in an experiment, never before
tested on humans. One way to help overcome this belief is by
educating the ‘well’ public about the necessity and positive
aspects of trials (Baum, 1993; Saunders et al, 1994). The need for
such action is supported in a recent study that explored the atti-
tudes of 20 women with breast cancer to trials (Ellis and Butow,
1998). The women did not have a good understanding of the
necessity for trials, nor did they understand the need for random-
ization of treatments.
A number of studies have examined the problem of informed
consent and trials but few have focused on the reasons why
patients with cancer accept, or decline, trial entry. Among the
factors that have been identified for acceptance of trial participa-
tion are the hopes that the new treatment will be of benefit to them,
and that it will be of benefit to others (Penman et al, 1984;
Kardinal, 1994; Slevin et al, 1995). Reasons for declining partici-
pation include a preference for a specific treatment arm and fear
of randomization (Penman et al, 1984; Llewellyn-Thomas et al,
1991; Jenkins et al, 1999). This paper examines some of the
reasons given by patients for accepting or declining entry to
different types of randomized trials of cancer therapy and is part of
a study being conducted in the UK that aims to improve communi-
cation between clinicians and patients when trials are discussed.
MATERIALS AND METHODS
Questionnaire
The questionnaire used was a similar design to that developed by
Penman and colleagues (Penman et al, 1984) and piloted on 50
patients with cancer who had agreed to participate in cancer trials.
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following the discussion of randomized trials with the clinician
and completed by the patient at home. The layout of the question-
naire is shown in Appendix 1. First, patients indicated whether or
not they had agreed to take part in a randomized trial or if they did
not know. Next the questionnaire listed 16 possible reasons that
might have influenced the decision to either accept or decline
treatment. For each statement patients registered their agreement
or disagreement on a scale of 1 (strongly agree) to 5 (strongly
disagree). Finally, patients indicated the most important reason for
their decision to accept or decline to take part in the trial.
Sample
Two hundred and forty patients with cancer and eligible to partici-
pate in randomized clinical trials were invited to join the main study.
They comprised newly diagnosed and relapsed patients referred to
17 senior clinicians (three specialist breast surgeons, five medical
oncologists and nine clinical oncologists) at district general and
university teaching hospitals. Nineteen patients declined to partici-
pate in the communication study and, of the 221 who took part, 204
(92.3%) returned the questionnaires. Tables 1 and 2 show the char-
acteristics of these patients, with breast cancer patients forming 55%
of the total sample. The high percentage of patients with breast
cancer probably reflects the large numbers of trials currently being
conducted in this common tumour site. Few patients had previous
trial experience (11/204, 5.4%) or previous experience of
chemotherapy (17/204, 8.3%). Only nine patients were expecting to
discuss trials with the clinician during the consultation.
Method
The design and method for the main study have been described
elsewhere in detail (see Jenkins et al, 1999). The study had the
approval of the Trent Multi Regional Ethic Committee and the
Local Ethic Committees of the participating hospitals. Before the
consultation, patients completed three questionnaires: a Patient
Information Needs questionnaire, a Patients’ Attitudes to
Randomised Clinical Trials questionnaire and the Speilberger State
Trait Anxiety Inventory (STAI). The consultations were audiotaped
and the patient was subsequently given two further questionnaires
to complete and return by post. One of the questionnaires examined
patients’ satisfaction with the consultation and the other reasons for
accepting or declining to enter a clinical trial. During the consulta-
tion the clinician discussed the randomized clinical trial (RCT)
suitable for that patient (e.g. ATAC, QASAR etc.) and in some
cases a research nurse was present to provide additional informa-
tion. In addition, most patients received information sheets about
the treatment trial either during or following the consultation. The
data presented in this paper are from the postal questionnaire
(Appendix 1), examining the reasons why patients agreed or
declined to participate in RCTs and whether the decision was influ-
enced by the type of trial on offer. The data were analysed using a
standard SPSS package. A report of the findings from the main
study will be available later in the year.
RESULTS
Overall, 147/204 (72.1%) patients accepted entry to a clinical trial,
51/204 (25%) declined and 6/204 (2.9%) indicated that they did not
know. This uncertainty may refer to the fact that they were still
undecided or that they were unsure whether they had agreed to
participate in a trial. Information sheets were given to 157/204
(77%) patients about the trial during the consultation. Of the 47
patients who did not receive an information sheet, 29/47 (64.4%)
agreed to participate in a trial and 16/47 (35.6%) declined. In
addition, a third of patients 68/204 (33.3%) had extra information
provided to them by a research nurse or trial coordinator and, of
these, 55/68 (80%) agreed to participate and 13/68 (19.1%)
declined. The number of patients with previous trial experience was
11 (5.4%), and of these only one declined and 15/17 (88.2%) patients
who had previous experience of chemotherapy took part in a trial.
There were no differences between those that accepted or declined
trial entry according to marital status, age or level of anxiety.
Reasons for accepting or declining trial entry
Table 3 displays the frequency (expressed as percentage) of agree-
ment to each statement according to whether patients accepted or
declined trial entry. The categories ‘strongly agree’ and ‘agree to
some extent’ were combined and differences between the groups
analysed using the Mann–Whitney test for non-parametric data.
Table 4 shows the most important reason given by patients for
deciding to accept or decline trial entry. The results shown in the
following tables exclude the six patients who did not know
whether they were in a trial or not.
Altruism and trust in the doctor are seen as the most important
reasons for accepting entry to a trial, whereas preference for the
doctor choosing treatment rather than randomization are cited
for declining a trial. A total of 35 different kinds of trial were
discussed and because of the small numbers in some of the trials
they were divided into four broad categories for analysis:
1. Chemotherapy
2. Radiotherapy
3. Hormone therapy
4. Miscellaneous.
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Table 1 Age and sex distribution (n = 204)
Age range Male n (%) Female n (%)
>25 years 3 (1.5)
25–44 years 9 (4.4) 19 (9.3)
45–64 years 22 (10.8) 84 (41.2)
over 65 years 28 (13.7) 39 (19.1).
Table 2 Cancer site distribution (n = 204)
Cancer site n (%)
Breast 112 (55)
Prostate 23 (11)
Testicular 15 (7)
Lung 7 (3)
Colorectal 15 (7)
Ovarian 18 (9)
Melanoma 2 (1)
Lymphoma 2 (1)
Bladder 4 (2)
Pancreas 5 (2.5)
Brain 1 (0.5)The participation rates for these categories are shown in Table 5.
There was a lower rate of acceptance for the chemotherapy and
radiotherapy trials compared with the hormone treatment trials.
This was not necessarily due to the relative acceptability of the
different treatments per se, but because of the trial design. Some
trials involved a placebo and others a ‘no treatment’ arm. A further
analysis was performed to examine this issue, with trials broadly
classified into three categories, those with:
1.Two or more active treatment arms
2.A ‘no treatment arm’
3.A placebo arm.
The acceptance rates for these categories are shown in Table 6.
There was a significantly higher acceptance rate for trials with an
active treatment arm, 79/98 (80.6%) compared with those with no
treatment arm 46/76 (60.5%), c2 test, P= 0.003. Surprisingly the
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Table 3The frequency (expressed as percentage) of agreement to each statement according to whether patients accepted or declined trial
entry.
Statement Accept trial Decline trial P-value
(n = 147) (n = 51)
1. I thought the trial offered the best 82.3% 11.8% 0.0001
treatment available (121) (6)
2. I believed the benefits of 78.9% 11.8% 0.0001
treatment in the trial would (116) (6)
outweigh the side-effects
3. I was satisfied that either 81% 13.7% 0.0001
treatment in the trial would be (119) (7)
suitable
4. I was worried that my illness 17% 9.8% 0.24
would get worse unless I joined (25) (5)
the trial
5. The idea of randomization 38.1% 62.7% 0.049
worried me (56) (32)
6. I wanted the doctor to choose my 51% 76.5% 0.0039
treatment rather than be (75) (39)
randomized by computer
7. The doctor told me what I 95.9% 88.2% 0.0553
needed to know about the trial (141) (45)
8. I trusted the doctor treating me 97.3% 94.1% 0.2935
(143) (48)
9. I was given too much information 7.5% 7.8% 0.0982
to read about the trial (11) (11)
10. I was given enough information 81.6% 56.9% 0.0003
to read about the trial (120) (29)
11. I knew I could leave the trial at 97.3% 90.2% 0.0345
any time and still be treated (143) (46)
12. I did not feel able to say no 10.2% 15.7% 0.1039
(15) (8)
13. I wanted to help with the doctor’s 92.5% 45.1% 0.0001
research (136) (23)
14. I feel that others with my illness 97.3% 58.8% 0.0001
will benefit from the results of the (143) (30)
trial
15. The doctor wanted me to join the 52.4% 31.4% 0.0144
trial (77) (16)
16. Others, e.g. family or friends 43.5% 3.9% 0.0002
wanted me to join the trial (64) (2)
Table 4Values are numbers (percentage) of patients
Top reasons for accepting trial entry n (%)
n= 138 (nine missing cases)
I feel that others with my illness will benefit from the results of the trial 34 (23.1)
I trusted the doctor treating me 31 (21.1)
I thought the trial offered the best treatment available 24 (16.3)
Top reasons for declining trial entry n (%)
n= 47 (four missing cases)
I trusted the doctor treating me 11 (21.6)
The idea of randomization worried me 10 (19.6)
I wanted the doctor to choose my treatment rather than be 9 (17.6)
randomized by computerrate of acceptance to the placebo trials was high, but it should be
noted that 19/22 (86.3%) of the patients were all offered the same
trial for prostate cancer by one female clinician.
DISCUSSION
The results show that the majority of patients offered entry into a
trial accepted. The main reason for participating was that the treat-
ment would benefit others in the future. However, this reason was
closely followed by trust in the doctor. The importance of altruism
as a motivating factor complements previous studies that exam-
ined patients considering hypothetical and non-cancer treatment
trials (Mattson et al, 1985; Welton et al, 1999). Altruism is also
cited as a motivating factor for participating in phase I cancer trials
where there is no long-term benefit for the patient (Kardinal,
1994). Whilst it is possible that patients with cancer are selfless,
one must also consider such concepts as social desirability. Social
desirability depends on a number of factors including sex, cultural
background and the specific question asked. If patients believe
another will read their responses, in order to be viewed in a good
light, they may give a socially desirable response (Streiner and
Norman, 1989).
‘Trust in the doctor’ was the second most frequently endorsed
reason for joining a cancer trial. This finding has remained stable
for over a decade and forms an important part of the doctor–
patient relationship (Penman et al, 1984). The provision of faith
and hope is seen as a central feature of a ‘healing’ relationship and
are powerful agents in their own right. Patients with cancer are
faced with a life-threatening illness and invest a lot of faith in the
doctor. Lupton (1996) notes that although patients judged the
doctor’s medical knowledge to be an important feature it was not
the essential characteristic that made a ‘good’ doctor. The key
features considered by the majority of patients were trust and
interpersonal skills, especially listening and communication.
Remarkably, ‘trust in the doctor’ was also cited as the main
reason for declining to participate in a trial. In the absence of
detailed interviews the patients’ interpretation of this phrase is
unclear. Perhaps during the discussion patients felt that the doctor
was unenthusiastic about the trial. Llewellyn-Thomas and
colleagues (Llewellyn-Thomas et al, 1991) suggested that cancer
patients who agree to enter clinical trials might be more suscep-
tible to the clinicians’ enthusiasm for the trial. Alternatively, the
clinician may have provided the patient with an unbiased, objec-
tive view stressing the voluntary nature of the study. Patients may
have over interpreted this equipoise to mean that ‘standard
treatment’ was better than the experimental arm and would not
compromise survival. There is evidence that cancer patients some-
times overestimate the benefits of standard therapies (Sheldon et
al, 1993). Other reasons given for declining to participate in a trial
were a fear of randomization and preference for the doctor to
choose the treatment. These two reasons combined related to the
same issue – the dislike of the idea that the choice of treatment
would be based on chance. What one does not know is whether
patients declined because they did not understand the concept
of randomization or because they did understand the concept.
Previous studies would suggest it is the former reason combined
with either a poor explanation of the concept by the doctor, or too
explicit an explanation (Corbett et al, 1996). The preference for
the doctor choosing the treatment was not exclusive to the
decliners. Fifty-one per cent of those who agreed to a trial indi-
cated that they would have preferred the doctor to choose the treat-
ment. This was reported as one of the less appealing aspects of
randomized trials in previous research (Slevin et al, 1995). The
emphasis given to chance in the explanation of the concept of
randomization is another cause of unease amongst patients and
the general public (Corbett et al, 1996; Fallowfield et al, 1998;
Featherstone and Donovan, 1998).
The differences between those who accepted and those who
declined trial entry are shown by their response to the statements
in the questionnaire. Those who decided to participate in a trial
agreed more with the statements that emphasized the benefits of
treatment, and were worried that their illness would get worse if
they did not join. They appeared to be more influenced by the
doctor, family and friends than those who declined and, further-
more, agreed that they wanted to help with the doctor’s research.
Those who declined were somewhat less satisfied with the
amount of written information given to them about the trial,
but there was no statistical difference between the groups. The
decliners had more reservation about the treatment being
randomized and did not agree that the trial offered the best
available treatment.
Although the subgroups were unequal, the acceptance rates to
the trials differed according to the type of treatment and type of
trial. The highest acceptance rate was recorded for the hormone
trials of different treatments compared with the chemotherapy and
radiotherapy studies. Perhaps patients view chemotherapy and
radiotherapy as short-term intensive treatments, which are more
intrusive and time-consuming. Additionally, clinicians may under-
state the potential severity of hormone treatment. Side-effects
associated with hormone therapy have not been the subject of
systematic evaluation to the same extent as chemotherapy
(Leonard et al, 1996), whereas discussion of ‘serious’ side-effects
such as nausea, vomiting and hair loss are talked about more
frequently for chemotherapy treatments (Jenkins et al, 1999).
When the trials were categorized according to trial design, signifi-
cantly more patients declined entry to a trial with no treatment
arm. This type of study is often the most controversial and of
course the discussion of these trials often poses the biggest
problem for doctors (Cook-Gotay, 1991).
It was somewhat surprising to find that 23% of patients were not
provided with a written information leaflet despite the fact that this
is a mandatory requirement for ethics approval of any RCT, and
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Table 5 Values are numbers (%) of patients
Trial category n Accept Decline
Chemotherapy 90 60 (66.7%) 30 (33.3%)
Radiotherapy 25 15 (60%) 10 (40%)
Hormone therapy  76 65 (85.5%) 11 (14.5%)
Miscellaneous 7 7 (100%)
Table 6 Values are numbers (%) of patients
Trial category  n Accept Decline
Active treatment arms  98 79 (80.6) 19 (19.4)
No treatment arm  76 46 (60.5) 30 (39.5)
Placebo arm  24 22 (91.7) 2 (8.3)that the clinicians knew that their consenting procedures were
being scrutinized during the study. The results from the study show
that patients are generally very willing to participate in studies but
that type of trial and probably communication style of doctor or
nurse explaining the study exerts a considerable influence on
patients’ preparedness to accept or decline.
ACKNOWLEDGEMENTS
The authors would like to thank Professor Robert Souhami who
commented on early drafts of the paper, the clinicians at
University College London Hospitals, Southend, Hillingdon,
Worthing and Brighton District General Hospitals for participating
in the study and especially the patients. This work is part of a
project funded by the NHS R&D programme. Lesley Fallowfield
is supported by the Cancer Research Campaign.
REFERENCES
Baum M (1993) Clinical trials are ethically impossible. Lancet 341: 812–813
Cook Gotay C (1991) Accrual to cancer clinical trials: directions from the research
literature. Soc Sci Med 33: 569–577
Corbett F, Oldham J and Lilford R (1996) Offering patients entry in clinical trials:
preliminary study of the views of prospective participants. J Med Ethics 22:
227–231
Ellis PM and Butow P (1998) Focus group interviews examining attitudes to
randomised trials among breast cancer patients and the general community.
Aust NZ J Public Health 22: 528–531
Fallowfield LJ, Ratcliffe D and Souhami RL (1997) Clinicians’ attitudes to clinical
trials of cancer therapy. Eur J Cancer 33: 2221–2229
Fallowfield LJ, Jenkins V, Brennan C, Sawtell M, Moynihan C and Souhami RL
(1998) Attitudes of patients to clinical trials of cancer therapy. Eur J Cancer
34: 1554–1559
Featherstone K and Donovan J (1999) Random allocation or allocation at random?
Patients’ perspectives of participation in an RCT. Br Med J 317: 1177–1180
Hamilton C (1992) Ethical and practical problems in trials testing treatment for pre-
malignant conditions: breast cancer as a model. In: Introducing New Treatments
for Cancer. Practical, Ethical and Legal Problems, Williams CJ (ed),
pp. 315–322. Wiley, London
Jenkins VA, Fallowfield LJ, Souhami A and Sawtell M (1999) How do doctors
explain randomised clinical trials to their patients? Eur J Cancer 35: 1187–1193
Kardinal CG (1994) Ethical issues in cancer clinical trials. J LA State Med Soc 146:
359–361
Leonard RC (1997) The advancement of high dose chemotherapy and dose
intensification schedules. Ann-Oncol 8 (Suppl 3): S3–6
Leonard RCF, Lee L and Harrison ME (1996) Impact of side-effects associated with
endocrine treatments for advanced breast cancer: clinicians’ and patients’
perceptions. Breast 5: 259–264
Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S and Erlichman C (1991)
Patients’ willingness to enter clinical trials: measuring the association with
perceived benefits and preference for decision participation. Soc Sci and Med
32: 35–42
Lupton D (1996) Your life in their hands: trust in the medical encounter. In: Health
and the Sociology of Emotions, James V and Gabe J (eds), pp. 157–172.
Blackwell Press, Edinburgh
Mattson ME, Curb DJ, McArdle R and the Aspirin Myocardial Infarction Study
and Beta Blocker Heart Attack Trial Research Groups (1985) Participation
in a clinical trial: the patients’ point of view. Controlled Clin Trials 6:
156–167
Penman DT, Holland JC, Bahna GF, and Morrow G et al (1984) Informed consent
for investigational chemotherapy: patients’ and physicians’ perceptions. J Clin
Oncol 2: 849–855
Saunders CM, Baum M and Houghton J (1994) Consent, research and the doctor–
patient relationship. In: Gillon R (Ed) Principles of Health Care Ethics.
Saunders C (1996) Clinical trials: ethical, legal and practical considerations. In:
Medico-legal Essentials in Healthcare, Payne-James J, Dean P and Wall I
(eds), pp. 161–169. Churchill Livingstone, Edinburgh
Sheldon JM, Fetting JH and Siminoff LA (1993) Offering the option of randomised
clinical trials to cancer patients who overestimate their prognoses with standard
therapies. Cancer Invest 11: 57–62
Slevin M, Mossman J, Bowling A, Leonard R, Steward W, Harper P, Mclllmurray M
and Thatcher N (1995) Volunteers or victims: patients’ views of randomised
cancer clinical trials. Br J Cancer 71: 1270–1274
Smyth JF, Mossman J, Hall R, Hepburn S, Pinkerton R, Richards M, Thatcher N and
Box J (1994) Conducting clinical research in the new NHS. Br Med J 309:
457–461
Stenning S (1992) The ‘uncertainty principle’: selection of patients for cancer
clinical trials. In: Introducing New Treatments for Cancer. Practical, Ethical
and Legal Problems, Williams CJ (ed), pp. 161–172. Wiley, London
Streiner DL and Norman GR (1989) Health Measurement Scales. A Practical Guide.
Oxford Medical Press, Oxford
Taylor KM and Kelner M (1987) Interpreting physician participation in
randomised clinical trials: the physician orientation profile. J Health Soc Beh
28: 389–400
Toynbee P (1997) Random clinical trials are one of life’s biggest gambles. BMA
News Rev 50: 50
Welton AJ, Vickers MR, Cooper JA, Meade TW and Marteau TM (1999) Is
recruitment more difficult with a placebo arm in randomised controlled trials?
A quasi-randomised, interview-based study. Br Med J 318: 1114–1117
Participation in cancer therapy trials 1787
British Journal of Cancer (2000) 82(11), 1783–1788 © 2000 Cancer Research CampaignAppendix 1: Accept and decline questionnaire
CONFIDENTIAL ID.......…
CLINICAL TRIALS QUESTIONNAIRE
We are interested in the reasons why patients accept or decline to take part in clinical trials/studies. We would be grateful if you would fill in this questionnaire.
It will not be shown to your doctor or any of the staff at the hospital. A pre-paid envelope is provided for the return of the form.
Yes No Do Not Know
First, we would like to know if you have agreed to take part in a clinical trial/study? n n n n n n
Below are some reasons that may have influenced your decision to accept or decline to take part in a clinical trial/study. Please answer each question and tick
the box that shows most clearly how you feel.
Strongly Agree to Disagree to Strongly
agree some extent Unsure some extent disagree
1) I thought the trial/study offered the
best treatment available. n n n n n n n n n n
2) I believed the benefits of treatment in the trial/study
would out-weigh any side-effects. n n n n n n n n n n
3) I was satisfied that either treatment in the trial/study
would be suitable for me. n n n n n n n n n n
4) I was worried that my illness would get worse
unless I joined the trial/study. n n n n n n n n n n
5) The idea of randomisation worried me. n n n n n n n n n n
6) I wanted the doctor to choose my treatment rather n n n n n n n n n n
than be randomised by computer.
7) The doctor told me what I needed to know about n n n n n n n n n n
the trial.
8) I trusted the doctor treating me. n n n n n n n n n n
9) I was given too much information to read about n n n n n n n n n n
the trial
10) I was given enough information to read about the n n n n n n n n n n
trial
11) I knew that I could leave the trial/study at any
time and still be treated. n n n n n n n n n n
12) I did not feel able to say no. n n n n n n n n n n
13) I wanted to help with the doctors research. n n n n n n n n n n
14) I feel that others with my illness
will benefit from the results of the trial. n n n n n n n n n n
15) The doctor wanted me to join the trial/study. n n n n n n n n n n
16) Others, e.g. family or friends
wanted me to join the trial/study. n n n n n n n n n n
Which was the most important reason for you out of the list? (Please give number)____________
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